Abstract Title: currently loading...

information currently loading...

close
Loading ... please wait
timer Loading ... please wait

Vascular Diseases & Diabetic Retinopathy I

10:30 - 12:00 | 05 September | Room: Speakers' Corner.

Back to Previous

10:30Analysis of retinal layer thickness and choroidal thickness in diabetic macular oedema treated with ranibizumab or aflibercept
S. Oruc Dundar Turkey
10:30Anterograde optic neuropathy and associated retrograde degeneration after branch retinal vein occlusion
S. Yu Switzerland
10:30Automated detection and quantification of spectral domain optical coherence tomography hyper-reflective foci in eyes with retinal vein occlusion
C. Mitsch Austria
10:30Changes in systemic oxidative stress in response to intravitreal anti-vegf therapy for patients with retinal vein occlusions
D. Hwang Taiwan
10:30Educational tool kit for diabetic eye disease
O. Galvin Ireland
10:30Evaluating the impact of a new national diabetic retinopathy screening programme on patient knowledge of HbA1c following referral to a regional treatment centre
J. Hui Min Singapore
10:30Increased risk of cancer in patients with retinal vein occlusion: a 12-year nationwide cohort study
M. Kim South Korea
10:30Intravitreal bevacizumab responsiveness after dexamethasone implants in diabetic macular edema patients previously refractory to intravitreal bevacizumab
J. Kwon South Korea
10:30Long term effects of pan-retinal photocoagulation in diabetic retinopathy in choroid, retina and in visual field
I. Pacheco Soares Carneiro Portugal
10:30Real-time data on the clinical outcomes of fluocinolone acetonide (Iluvien) implant use in chronic diabetic macular oedema in pseudophakic patients
M. Fenech UK
10:30Spectral-domain optical coherence tomography reveals subtle vascular changes in patients with Waldenström´s macroglobulinemia
A. Willerslev Denmark
10:30The comparison of reduced fluence photodynamic therapy with modified or conventional irradiation area for central serous chorioretinopathy
M. Hayashida Japan
10:30The impact of prior therapies on visual acuity outcomes achieved with the 0.19 mg fluocinolone acetonide implant – insights from the UK Medisoft audit study
C. Bailey UK
10:30The quantification of retinal inflammatory biomarkers after treatment of naïve diabetic macular edema.
S. Bini Italy
13:15Imaging analysis with optical coherence tomography angiography after primary repair of macula-off rhegmatogenous retinal detachment
C. Tsen Taiwan
Back to Previous

Want to find out more about EURETINA activities?

Contact us
© EURETINA All rights reserved